Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.

Abstract excerpt

The presence of activating gene mutations in the epidermal growth factor receptor of non-small cell lung cancer patients is predictive (improved progression-free survival and improved response rate) when treated with small molecule tyrosine kinase inhibitors such as gefitinib, erlotinib and afati...

Topics

• Afatinib
• Antineoplastic Agents
• Carcinoma, Non-Small-Cell Lung
• Clinical Trials as Topic
• ErbB Receptors
• Gefitinib
• Humans
• Lung Neoplasms
• Mutation
• Protein Kinase Inhibitors
• Quinazolines